摘要
目的应用门冬氨酸鸟氨酸对肝性脑病的临床疗效及安全性进行观察。方法 2000年4月2009年11月,将60例肝硬化肝性脑病患者分为对照组和治疗组,对照组给予常规精氨酸治疗,治疗组在对照组基础上加门冬氨酸鸟氨酸10g/d,静脉滴注,连续7d。观察治疗前后神志变化、血清氨基转移酶(ALTAST)、血清白蛋白(ALB)等指标变化。结果治疗组经门冬氨酸鸟氨酸治疗后神志改变、ALT、AST明显优于治疗前(P<0.05)。结论门冬氨酸鸟氨酸治疗肝性脑病疗效确切,且对肝功能有改善作用,副反应小。
Objective To evaluate the clinical efficacy and safety of L-ornithine-L-aspartate treating the patients with hepatic encephalopathy.Methods Sixty patients with hepatic encephalopathy from April 2000to November 2009 were randomly divided into treatment group and control group with 30patients in each.The patients in the control group were treated with the routine therapy of arginine,while the ones in the treatment group were treated with L-ornithine-L-aspartate besides the routine therapy for one week injection（10.0g dissolved in 5%glucose 250mL by in-travenous infusion once daily）,the liver function and mind change were observed in all patients at the onset and one week after treatment respectively.Results One week after the treatment,the liver function（ALT、AST）and mind change of patients differed statistically significantly from that before the treatment（P0.05）.Conclusion L-ornithine-L-aspartate is effective for the patients with minimal hepatic encephalopathy,which could improve the liver function with little side effect.
出处
《华西医学》
CAS
2010年第9期1602-1603,共2页
West China Medical Journal
关键词
门冬氨酸鸟氨酸
肝硬化
肝性脑病
L-ornithine-L-aspartate
Hepatic encephalopathy
Cirrhosis
